







INTERNATIONAL CONFERENCE ON PHARMA AND MEDICAL DEVICE SECTOR



25 - 27 April 2022 Dr. Ambedkar International Centre, New Delhi



OVERALL PROGRAM INDIA PHARMA & INDIA MEDICAL DEVICE

25 - 27 April 2022 | Dr. Ambedkar International Centre, New Delhi

25 - 27 April 2022 Dr. Ambedkar International Centre, New Deini			
DATE / TIME	EVENT		
	DAY 1, 25 th April 2022, Monday		
1000-1130	Inaugural Session and Awards Ceremony: India Pharma 2022 & India Medical Device 2022		
1000-1100	Inaugural Session		
1100-1130	Pharma & Medical Device Awards 2022		
1130-1200	Tea Break		
1200-1400	INDIA PHARMA CEO Roundtable with Hon'ble Minister for Chemicals & Fertilizers, Dept. of Pharmaceuticals,		
	Ministry of Chemicals & Fertilizers. Govt. of India (By Invitation Only)		
1230-1330	States meeting with Medical Device Company CEOs		
1200-1400	Workshop - Materio Vigilance Program of India (MvPI) by IPC		
1400-1500	Lunch break		
1500-1700	INDIA MEDICAL DEVICE CEO Roundtable with Hon'ble Minister for Chemicals & Fertilizers, Dept. of		
	Pharmaceuticals, Ministry of Chemicals & Fertilizers. Govt. of India (By Invitation Only)		
1500-1600	States meeting with Pharma Company CEOs		
1715-1815	State Drug Regulators Meet		
1815-1915	International Drug Regulators Meet		
1930-2100	Cultural Programme followed by Networking Dinner		
	DAY 2, 26 th April 2022, Tuesday		
	INDIA PHARMA 2022 Conference "Indian Pharma - Vision 2047"		
1000-1130	IP Theme Session: Indian Pharma - Vision 2047		
1145-1315	IP Session 2: Building Resilient Supply Chains		
1315-1415	Lunch break		
1430-1600	IP Session 3: Evolving Health Tech Space: Some Success Stories		
1615-1745	IP Session 4: Encouraging R&D Ecosystem: Building collaborations		
1800-1930	Investor Forum by Invest India: Pharma		
	DAY 3, 27 th April 2022, Wednesday		
	MEDICAL DEVICE 2022 Conference "Transforming Healthcare through innovation and integrated services".		
1000-1115	IMD Session 1 A: Theme Session: "Transforming Healthcare through innovation and integrated services".		
1115-1200	IMD Session 1 B: Precision Healthcare (Knowledge Sharing Session: Case Studies)		
1215-1345	IMD Session 2: Establishing Patient-Centred Outcomes of Care for Promoting Value based Procurement		
1345-1420	Lunch Break		
1430-1600	IMD Session 3: Manufacturing, Demand & Global Supply Chain of Medical Devices		
1615-1730	IMD Session 4: R&D and Innovation in MedTech: Some Success Stories		
1745-1915	Investor Forum by Invest India: Medical Devices		

KEY ACTIVITIES OF INDIA PHARMA & INDIA MEDICAL DEVICE 2022

Inaugural Session

CEOs Roundtable

Drug Regulators Meet India Pharma & India Medical Device Awards

Thematic Conference Sessions

Investor Forum by Invest India

Startup Showcase Media Interaction















ABOUT INDIA PHARMA & INDIA MEDICAL DEVICE 2022

The Department of Pharmaceuticals, Ministry of Chemicals & Fertilizers, Government of India, along with the Federation of Indian Chambers of Commerce & Industry (FICCI) has been actively working towards growth of Pharma & Medical Device sector. Since the objective has always been to encourage and bring forward best technology solutions and manufacturing, therefore, Department of Pharmaceuticals announced India Pharma & India Medical Device series of events which is an annual activity. The 7th edition of International Conference on Pharmaceutical & Medical Device sector i.e INDIA PHARMA 2022 & INDIA MEDICAL DEVICE 2022 is scheduled from 25-27 April, 2022.

Special focus during the 7th edition of India Pharma & India Medical Device would be the Investor Forum by Invest India.

The objective of India Pharma & India Medical Device 2022 is to:

- Endeavor to address industry issues and to create a platform to recommend solutions
- Facilitate sharing of knowledge and best practices
- Promote India as a Manufacturing hub in the Pharmaceutical and Medical Devices Sector
- Establish India as a premier global healthcare destination and attract investments
- Provide a platform to network and collaborate
- Identify new priority areas and deliberate upon them










PHARMA SECTOR OVERVIEW

India being the largest provider of generic medicines globally, occupying a 20% share in global supply by volume, supplying 62% of Global Vaccine demand has a prominent and rapidly growing presence in the global pharmaceuticals industry. India ranks 3rd worldwide for production by volume and 14th by value in Pharmaceutical sector .India is home to more than 3,000 pharma companies with a strong network of over 10,500 manufacturing facilities offering more than 60,000 generic brands across 60 therapeutic categories. India has the highest number of US-FDA compliant Pharma plants outside of USA and its API industry is third largest in the world.

The current market size of the Pharmaceutical Industry in India is estimated to be above USD 50 Bn (2020-21) with a growth rate of 10-12%. India is well on track towards achieving its growth target of reaching USD 120-130 Bn over the next decade (by 2030), and thus contributing significantly in the GDP of the 5 Trillion economy of India.







INDIA PHARMA 2022 - CONFERENCE PROGRAM

Vision 2047: Transformative Roadmap for the Future

DAY 2, 26 th April 2022 (Tuesday)		
1000-1130	Theme SESSION: Indian Pharma: Vision 2047	
	Session Brief:	
	i. Where India Lifesciences Sector will be in 2047?	
	ii. What Sectors/technologies India will/should be leading in?	
	iii. What areas will India have global champions in - Innovative drugs, Biologicals, Complex generics/Biosimilars? Or any other vertical	
	iv. How to continue India's dominance as Pharmacy of the World	
	v. How can India come in top 3 countries for Patented medicines discovery & exports?	
	vi. How do we move from CT to real world evidence, to healthcare delivery at doorstep?	
	vii. What Institutional capabilities will India have by then? Reforms needed?	
1130-1145	BREAK	
1145-1315	SESSION 2: Building Resilient Supply Chains	
	Session Brief:	
	To seize these new opportunities, the Indian pharmaceuticals sector should focus on strengthening and diversifying its supply chain network. During COVID times, Pharma Supply Chain has been in the spot-light for last 2 years for good and bad reasons. We will attempt to understand the factors that lead to global supply chain disruption and what measures we are taking to make it robust and resilient going forward.	
	Key Discussion Points:	
	Key learnings from COVID-19 in making India a reliable supply chain partner	
	Need for diversified supply chain to ensure consistent supplies and managed volatility	
	Building visible, reliable and robust supply chain for domestic market	
	What are the major challenges being faced in supply chain while exporting and domestic supply	
	Is Industry 4.0 and digitization the next game changer	
	Impact of Geo-political events on supply chain namely localization of manufacturing, international transport	
	Understand GATISHAKTI plans	
	Support required from government for consistency and predictability in policy	

1315-1400	LUNCH BREAK
1400-1530	SESSION 3: Evolving Health Tech Space: Some Success Stories
	Session Brief:
	This session aims to present success stories of such entrepreneurs who have been able to commercialise their products and technology solutions in Health Tech space. The session will deliberate on Opportunities, Challenges, Regulatory support needed and Taxation/Financial edge to be competitive globally for the start-ups
	Key Discussion Points:
	 Presentation by AIML (Artificial and Machine based learning) Start-up's operating in India since 2016 and have created successful business models around it.
	Brief profile of each start-up and their current market size
	SIZE of the PRIZE: Potential these start-up's think India can achieve
	Their plans for future growth and job creation they can support going forward
	 Suggestions on support needed by them to place India at the highest pedestal of the AI value chain by 2025
	What national digital strategies can be implemented/what existing laws and policies can be amended
1530-1545	BREAK
1545-1715	SESSION 4: Ecosystem for R&D and Innovation: Building Collaborations
	Session Brief:
	Life sciences in India have witnessed huge progress. We need to catapult India into the global Research and Development and high value pharma space. The session will focus on deliberating on and defining the future roadmap to achieve the goal.
	Creating favourable regulatory environment to promote innovation
	Deliberate how can we improve access to quality infrastructure for sustainable clinical trials
	Strengthening Innovation clusters on the lines of mature global hubs like Boston and Singapore
	Identify ways to increase R&D financing resources to encourage pharmaceutical R&D
	 Identify ways to build commercial ecosystem through industry-academia collaboration, promote outcome-based research and international collaborations
	Develop accelerated pathways for R&D like in COVID times
	Potential areas for research- How to decrease effluent load, AMR, etc
	Moonshot Futuristic areas- rare diseases, biologics, frontal medicines, genomics, advanced therapeutics, etc.

INDIA MEDICAL DEVICE 2022 - CONFERENCE PROGRAM

Transforming Healthcare through innovation and integrated services

	DAY 3: 27 th April 2022 (Wednesday)
1000-1115	Session 1: Theme Session: "Transforming Healthcare through innovation and integrated services"
1115-1200	Session 1B: Precision Healthcare (Knowledge Sharing Session: Case Studies)
1000-1115	Session Brief:
	1. Healthcare moving from experiential to evidence-based care.
	2. MedTech companies are constantly using innovative measures to manage data lakes, carrying out big data analytics, churning software solutions to improve diagnosis and prognosis for continuous upgradation to be deployed in remote monitoring and tele ICU and Nuclear Medicine.
	3. Technological advancements like minimal invasive surgeries, transcatheter, wearable technologies, robotics surgery have led to reducing overall cost of care and better treatment outcomes. Similarly, innovation in IVDs has led to a better understanding of genomic sequencing and a shift from open to fully automated closed systems improving the speed of test outcomes and ensuring safety of the users and service providers.
	4. Digital technology is transforming the future of healthcare delivery as we march towards precision health.
	5. To adopt to these changes, clinicians/ health care professionals require, diversified skill sets and not just clinical acumen e.g., newer sets of clinical data analytics, understanding full scope software/ hardware and adoption of new surgical techniques. Hence, product innovation to be coupled with integrated services.
	Session 1B: Precision Healthcare (Knowledge Sharing Session: Case Studies/Patient Stories)
	Ventilator
	Blood management and COVID care
	Cardiovascular & Patient Monitoring
1215-1345	Session 2: Establishing Patient-Centered Outcomes of Care for Promoting Value based Procurement
	Session Brief:
	In Indian healthcare system, both the public and private sector have different models of MedTech procurement. In the public sector, qualification is based on technical specifications and the final decision is based on the lowest commercial quotation. However, procurement in the private health care sector is clearly moving away from traditional lowest price procurement strategies and product buying to quality, integrated services, entire life cycle of the equipment, entire episodic and long-term cost benefit as well as societal benefit. True Value-based procurement, however, remains in its initial stages of practical implementation as the level of understanding differs among stakeholders and health care providers are still struggling with practical implementation hurdles.
1430-1600	Session 3: Manufacturing, Demand & Global Supply chain of Medical Devices
	Session Brief:
	 Opportunities in the medical devices sector are immense, but to be able to position itself strongly in the post-pandemic world, India needs to continue its efforts to create an encouraging environment for domestic manufacturing of medical devices.
	Presently, per capita usage of Medical Device is 7.8 USD compared to global average of approx. 60 USD.

- Enhancing Health insurance coverage as per National Health Policy 2017, developing healthcare infrastructure as per National Infrastructure Pipeline 2020, Ayushman Bharat aspiration of creating 150000 primary healthcare/diagnostic center can significantly increase demand.
- It will be vital for India to re-strategize a long-term roadmap to promote this industry. The first focus should be on enhancing competency of the sector through skilling, upskilling and reskilling, in alignment with the medical and technological advancements. The second target should be expanding access and opportunities through collaborative policy support for both demand and supply side of the medical devices industry.
- The thrust of Government revolves around an attempt to make India Self Reliant and an export hub in the future. However, the medical device industry is at a nascent stage to be scaled up as a global exporter. Medical Device landscape is complex, the need of the hour is to attract more investments in the form of R&D and scientific manufacturing in the country. Upcoming Medical Device Parks in UP, MP, Tamil Nadu and Himachal Pradesh.
- Need of a Resilient supply chain.
- Creation of Conducive Environment for manufacturing (Ease of Doing Business with favourable & predictable manufacturing policies).
- Enhancing the tertiary healthcare infrastructure in metros and tier 1 cities and development of new primary healthcare infrastructure in Tier 2 & Tier 3 cities, supported by circulatory economy.
- Need Policy facilitating private participation to provide an impetus in strengthening the overall healthcare infrastructure and accessibility to healthcare service which will create demand.
- As per the Union Budget 2022, the Circular Economy transition is expected to help in productivity enhancement as well as creating large opportunities for new businesses and jobs. The action plans for ten sectors including electronic waste, are ready. Need to explore the scope of Circular Economy for medical electronics to meet the demands of the tier 2 and tier 3 cities.

1615-1730

Session 4: R&D and Innovation in MedTech

Session Brief:

The MedTech ecosystem is witnessing a paradigm shift and achieving rapid advances in technology that can be experienced both in incremental and disruptive ways. Some of these breakthrough technologies are focusing on augmenting features to make a product more useful while others are evolving completely new ways to meet the challenges in the emerging MedTech sector.

With the increasing cost of health care, more focus on value-based products and better access to newer offerings, it is imperative that the MedTech industry also equips itself with technology and digitization. Undoubtedly, these transformations are creating newer and better opportunities for innovation in the MedTech industry but also creating bigger challenges for the times to come.

In such a scenario, incentivizing investment in research and development (R&D) becomes imperative for developing capabilities for the future. This emphasizes the need for non-traditional partners to help the industry drive their innovation agendas and opens the door for adopting hybrid operating models along with creating Centre's of Excellence. In recent times we have observed a plethora of Unicorns emerging as innovators to create improved solutions. Centers of Excellence, Start-up accelerators programs, Start-up innovators program, innovate in India, new innovation and R&D policy are all significant steps in this direction that offers the MedTech industry with the rare opportunity to make India emerge as the hub of innovations in future.

ORGANISERS



Department of Pharmaceuticals, Ministry of Chemicals & Fertilizers, Government of India

The Department of Pharmaceuticals was created on the 1st of July in the year 2008 in the Ministry of Chemicals & Fertilizers with the objective to give greater focus and thrust on the development of pharmaceutical sector in the country and to regulate various complex issues related to pricing and availability of medicines at affordable prices, research & development, protection of intellectual property rights and international commitments related to pharmaceutical sector which required integration of work with other Ministries.



FICCI

FICCI is the voice of India's business and industry. Established in 1927, it is India's oldest and largest apex business organization. It serves its members from the Indian private and public corporate sectors and multinational companies, drawing its strength from diverse regional chambers of commerce and industry across states, reaching out to over 2,50,000 companies.



Invest India

Invest India is the National Investment Promotion and Facilitation Agency of India and acts as the first point of reference for investors in India. Invest India is transforming the country's investment climate by simplifying the business environment for investors. Its experts, specializing across different countries, sectors, and Indian states, handhold investors through their investment lifecycle - from pre-investment to after-care.

Invest India, set up in 2009, is a nonprofit venture under the Department for Promotion of Industry and Internal Trade, Ministry of Commerce and Industry, Government of India.

For Participation, Contact:

India Pharma 2022

Mr Rahul Mukherjee • M: +91 9711319047 • T: 011-23487517

E: lifesciences@ficci.com

www.indiapharmaexpo.in

India Medical Device 2022

Ms Pallavi Thakur • Deputy Director, FICCI

M: +91 99530 38483 • E: pallavi.thakur@ficci.com

Mr Sourabh Singh Shekhawat • Senior Assistant Director, FICCI

M: +91 78756 33551 • E: sourabh.shekhawat@ficci.com

Ms Beena Mulani, Executive Officer, FICCI

M: +91 99119 37797 • E: beena.mulani@ficci.com

www.indiamediexpo.in